Immuneering Corporation (NASDAQ:IMRX) Receives Consensus Rating of “Hold” from Brokerages

Immuneering Corporation (NASDAQ:IMRX) has received an average rating of “Hold” from the seven analysts that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $16.40.

Several research analysts have issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $11.00 price target on shares of Immuneering in a report on Tuesday, September 30th. Chardan Capital lifted their price target on Immuneering from $13.00 to $20.00 and gave the company a “buy” rating in a research report on Friday, September 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of Immuneering in a research note on Saturday, September 27th. Mizuho boosted their target price on Immuneering from $8.00 to $10.00 and gave the company an “outperform” rating in a research note on Wednesday, June 18th. Finally, Oppenheimer boosted their price target on Immuneering from $21.00 to $30.00 and gave the company an “outperform” rating in a report on Thursday, September 25th.

Insider Buying and Selling

In other news, Director Peter Feinberg purchased 7,500 shares of the stock in a transaction dated Tuesday, September 30th. The shares were purchased at an average cost of $7.03 per share, with a total value of $52,725.00. Following the acquisition, the director directly owned 149,266 shares of the company’s stock, valued at $1,049,339.98. This represents a 5.29% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders acquired 13,300 shares of company stock worth $93,729. Company insiders own 22.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Corient Private Wealth LLC purchased a new position in Immuneering in the second quarter worth about $215,000. Bridgeway Capital Management LLC raised its stake in shares of Immuneering by 57.9% during the second quarter. Bridgeway Capital Management LLC now owns 95,449 shares of the company’s stock valued at $322,000 after acquiring an additional 35,000 shares in the last quarter. Flower City Capital bought a new stake in shares of Immuneering during the second quarter valued at approximately $108,000. XTX Topco Ltd bought a new stake in shares of Immuneering during the second quarter valued at approximately $90,000. Finally, Jane Street Group LLC bought a new stake in shares of Immuneering during the first quarter valued at approximately $32,000. Hedge funds and other institutional investors own 67.65% of the company’s stock.

Immuneering Trading Down 7.4%

Shares of IMRX stock opened at $6.05 on Monday. The stock has a 50-day moving average of $5.68 and a 200-day moving average of $3.40. Immuneering has a 1-year low of $1.10 and a 1-year high of $10.08. The stock has a market cap of $251.50 million, a price-to-earnings ratio of -3.20 and a beta of 0.47.

Immuneering (NASDAQ:IMRX) last released its earnings results on Wednesday, August 13th. The company reported ($0.40) EPS for the quarter, hitting the consensus estimate of ($0.40). Sell-side analysts forecast that Immuneering will post -1.86 earnings per share for the current year.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.